Evolocumab Shows a Higher Reduction in LDL-C Than Alirocumab

Via Peters

At week 4, there was about a 61.6% decrease for individuals with hypercholesterolemia who do not attain low-density lipoprotein cholesterol and/or are intolerant to other lipid-lowering drugs. Alirocumab (Praluent) has reduced effectiveness compared with evolocumab (Repatha) for individuals with hypercholesterolemia who do not attain low-density lipoprotein cholesterol (LDL-C) and/or are […]